CD70 and renal cell carcinoma: For relapsed or refractory RCC and various lymphoma subtypes, CTX130 (NCT04502446) is an effective therapeutic strategy developed by CRISPR Therapeutics, Inc.CTX130 is a gene‐edited allogeneic CAR‐T cell therapy from a healthy donor targeting CD70, which is expressed in a wide range of solid and hematologic tumors The Phase 1 COBALT‐LYM trial is focused on evaluating the safety and efficacy of CTX130 for the treatment of patients with relapsed or refractory T‐cell lymphoma.